These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19708032)

  • 1. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
    Thomas DA; Kantarjian HM; Stock W; Heffner LT; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Pierce S; Lu B; Deitcher SR; O'Brien S
    Cancer; 2009 Dec; 115(23):5490-8. PubMed ID: 19708032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
    O'Brien S; Schiller G; Lister J; Damon L; Goldberg S; Aulitzky W; Ben-Yehuda D; Stock W; Coutre S; Douer D; Heffner LT; Larson M; Seiter K; Smith S; Assouline S; Kuriakose P; Maness L; Nagler A; Rowe J; Schaich M; Shpilberg O; Yee K; Schmieder G; Silverman JA; Thomas D; Deitcher SR; Kantarjian H
    J Clin Oncol; 2013 Feb; 31(6):676-83. PubMed ID: 23169518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
    Silverman JA; Reynolds L; Deitcher SR
    J Clin Pharmacol; 2013 Nov; 53(11):1139-45. PubMed ID: 23907766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias.
    Shah NN; Merchant MS; Cole DE; Jayaprakash N; Bernstein D; Delbrook C; Richards K; Widemann BC; Wayne AS
    Pediatr Blood Cancer; 2016 Jun; 63(6):997-1005. PubMed ID: 26891067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial.
    Schiller GJ; Damon LE; Coutre SE; Hsu P; Bhat G; Douer D
    J Adolesc Young Adult Oncol; 2018 Oct; 7(5):546-552. PubMed ID: 30239252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
    Hagemeister F; Rodriguez MA; Deitcher SR; Younes A; Fayad L; Goy A; Dang NH; Forman A; McLaughlin P; Medeiros LJ; Pro B; Romaguera J; Samaniego F; Silverman JA; Sarris A; Cabanillas F
    Br J Haematol; 2013 Sep; 162(5):631-8. PubMed ID: 23802738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study.
    Ollila T; Butera J; Egan P; Reagan J; Thomas A; Yakirevich I; MacKinnon K; Margolis J; McMahon J; Rosati V; Olszewski AJ
    Oncologist; 2022 Jul; 27(7):532-e542. PubMed ID: 35641232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy.
    Kaplan LD; Deitcher SR; Silverman JA; Morgan G
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):37-42. PubMed ID: 24252360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia.
    Douer D
    Oncologist; 2016 Jul; 21(7):840-7. PubMed ID: 27328933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
    Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H
    JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
    August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors.
    Yan Z; Zhu ZL; Qian ZZ; Hu G; Wang HQ; Liu WH; Cheng G
    Acta Pharmacol Sin; 2012 Jun; 33(6):852-8. PubMed ID: 22669119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
    Thomas DA; Sarris AH; Cortes J; Faderl S; O'Brien S; Giles FJ; Garcia-Manero G; Rodriguez MA; Cabanillas F; Kantarjian H
    Cancer; 2006 Jan; 106(1):120-7. PubMed ID: 16331634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.
    Silverman JA; Deitcher SR
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):555-64. PubMed ID: 23212117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
    Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vincristine sulfate liposomal injection for acute lymphoblastic leukemia.
    Raj TA; Smith AM; Moore AS
    Int J Nanomedicine; 2013; 8():4361-9. PubMed ID: 24232122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG; Shukla N; Kobos R; Steinherz L
    Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity.
    Deitcher OR; Glaspy J; Gonzalez R; Sato T; Bedikian AY; Segarini K; Silverman J; Deitcher SR
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):197-202. PubMed ID: 24417913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine.
    Davis T; Farag SS
    Int J Nanomedicine; 2013; 8():3479-88. PubMed ID: 24072970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.